Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Tait D. Shanafelt; Xin Victoria Wang; Curtis A. Hanson; Elisabeth Paietta; Susan O’Brien; Jacqueline Barrientos; Diane F. Jelinek; Esteban Braggio; Jose F. Leis; Cong Christine Zhang; Paul M. Barr; Amanda F. Cashen; Anthony R. Mato; Avina K. Singh; Michael P. Mullane; Richard F. Little; Harry Erba; Richard M. Stone; Mark Litzow; Martin Tallman; Neil E. Kay

doi:10.1182/bloodadvances.2024013474

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin TallmanNeil E. Kay

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	224-228
Number of pages	5
Journal	Blood Advances
Volume	9
Issue number	1
DOIs	https://doi.org/10.1182/bloodadvances.2024013474
State	Published - Jan 14 2025

Access to Document

10.1182/bloodadvances.2024013474

Cite this

Shanafelt, T. D., Wang, X. V., Hanson, C. A., Paietta, E., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A. K., Mullane, M. P., Little, R. F., Erba, H., Stone, R. M., Litzow, M., ... Kay, N. E. (2025). Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Blood Advances, 9(1), 224-228. https://doi.org/10.1182/bloodadvances.2024013474

@article{d6d80649d47b42afaa6def047eab940d,

title = "Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912",

author = "Shanafelt, {Tait D.} and Wang, {Xin Victoria} and Hanson, {Curtis A.} and Elisabeth Paietta and Susan O{\textquoteright}Brien and Jacqueline Barrientos and Jelinek, {Diane F.} and Esteban Braggio and Leis, {Jose F.} and Zhang, {Cong Christine} and Barr, {Paul M.} and Cashen, {Amanda F.} and Mato, {Anthony R.} and Singh, {Avina K.} and Mullane, {Michael P.} and Little, {Richard F.} and Harry Erba and Stone, {Richard M.} and Mark Litzow and Martin Tallman and Kay, {Neil E.}",

year = "2025",

month = jan,

day = "14",

doi = "10.1182/bloodadvances.2024013474",

language = "English",

volume = "9",

pages = "224--228",

journal = "Blood Advances",

issn = "2473-9529",

number = "1",

}

Shanafelt, TD, Wang, XV, Hanson, CA, Paietta, E, O’Brien, S, Barrientos, J, Jelinek, DF, Braggio, E, Leis, JF, Zhang, CC, Barr, PM, Cashen, AF, Mato, AR, Singh, AK, Mullane, MP, Little, RF, Erba, H, Stone, RM, Litzow, M, Tallman, M & Kay, NE 2025, 'Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912', Blood Advances, vol. 9, no. 1, pp. 224-228. https://doi.org/10.1182/bloodadvances.2024013474

TY - JOUR

T1 - Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

AU - Shanafelt, Tait D.

AU - Wang, Xin Victoria

AU - Hanson, Curtis A.

AU - Paietta, Elisabeth

AU - O’Brien, Susan

AU - Barrientos, Jacqueline

AU - Jelinek, Diane F.

AU - Braggio, Esteban

AU - Leis, Jose F.

AU - Zhang, Cong Christine

AU - Barr, Paul M.

AU - Cashen, Amanda F.

AU - Mato, Anthony R.

AU - Singh, Avina K.

AU - Mullane, Michael P.

AU - Little, Richard F.

AU - Erba, Harry

AU - Stone, Richard M.

AU - Litzow, Mark

AU - Tallman, Martin

AU - Kay, Neil E.

PY - 2025/1/14

Y1 - 2025/1/14

UR - http://www.scopus.com/inward/record.url?scp=85215292684&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2024013474

DO - 10.1182/bloodadvances.2024013474

M3 - Article

C2 - 39163612

AN - SCOPUS:85215292684

SN - 2473-9529

VL - 9

SP - 224

EP - 228

JO - Blood Advances

JF - Blood Advances

IS - 1

ER -

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Access to Document

Other files and links

Cite this